Project description
An eagle's eye for antibodies associated with rare diseases may revolutionise therapy
Neurodegenerative diseases are a large family of disorders characterised by progressive degeneration of the structure and function of the nervous system. While great strides have been made in understanding the causes and progression of many of these diseases, treatment and ultimately prevention is still quite challenging. Human-derived antibodies that can recognise threats with high specificity and mount a defence with minimal side effects hold great but largely unreleased potential to combat neurodegenerative disease processes. The Swiss biotech company Mabylon has developed powerful technologies to screen for some of the rarest antibodies. With the EU-funded HominAb project, scientists are laying the groundwork for commercialisation of their screening platform to target diseases including amyotrophic lateral sclerosis and frontotemporal dementia.
Objective
Neurodegenerative diseases are one of the disease fields with the highest unmet need. Decades of research have been invested in finding cures, however almost none have been successful. Antibodies have great therapeutic potential to treat these diseases as they are broadly applicable to specifically target different aspects of disease-causing processes. However, most of current non-human antibodies are limited by side-effects and a lack of specificity. Human-derived antibodies, derived from human blood samples, provide a solution for these limitations. They are naturally designed by the human immune system to fight toxic moieties with higher efficacy and specificity and are expected to have lower side-effects when compared to antibodies of non-human origin. However a large amount of blood samples is required to identify the rarest and most specific antibodies.
Mabylon is a biotechnology company that capitalizes on the human body’s own protective capability to generate antibodies against human disease. Mabylon’s unique screening platform allows identification of a “needle in the haystack” and develop fully human antibodies for diseases with high unmet medical need in the field of allergies and neurodegenerative diseases. Mabylon is currently developing several antibodies including an antibody for TDP-43, a toxic protein associated with diseases progression in ALS and FTD. ALS as a potential initial market could generate €110M in licensing revenue in 2021-2025 and €170M in royalties (5%) from 2026-2030. In addition, platform expansion towards other indications addresses a total neurodegenerative drug market worth €40B by 2022.
In the HominAb project, we will investigate our market positioning, the commercial landscape, preclinical development and licensing strategy in order to enable successful commercial maturation of our platform for neurodegenerative diseases.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences basic medicine immunology
- medical and health sciences clinical medicine allergology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
8952 SCHLIEREN
Switzerland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.